GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general med...
An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT06666491
- Locations
- 🇮🇳
GSK Investigational Site, Surat, India
A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 200
- Registration Number
- NCT06663436
- Locations
- 🇰🇪
GSK Investigational Site, Kericho, Kenya
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 4
- Registration Number
- NCT06655818
- Locations
- 🇰🇷
GSK Investigational Site, Ulsan, Korea, Republic of
A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 23
- Registration Number
- NCT06640049
- Locations
- 🇨🇳
GSK Investigational Site, Zhengzhou, China
Phase 1, FTIH, Study to Evaluate the Safety, Tolerability, Blood Sample of Single Ascending Dose of GSK4771261 in Healthy Participants and Autosomal Dominant Polycystic Kidney Disease Participants
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 84
- Registration Number
- NCT06625476
A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 38
- Registration Number
- NCT06625489
A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD)
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 750
- Registration Number
- NCT06614725
- Locations
- 🇮🇳
GSK Investigational Site, Vadu Budruk Pune, India
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-09-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 393
- Registration Number
- NCT06613698
- Locations
- 🇬🇧
GSK Investigational Site, Middlesbrough, United Kingdom
A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 90
- Registration Number
- NCT06597344
- Locations
- 🇺🇸
GSK Investigational Site, Bountiful, Utah, United States
A Study to Evaluate the Effect of Itraconazole on the Concentration of GSK3923868 in the Blood in Healthy Participants
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT06597500
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath